Update: GenMark (GNMK) Soars on Q4 and Full Year 2018 Results
- Revenues of $70.8M were 35% over 2017 Results
- Q4 Revenues were $19.4M an increase of 21% over prior year.
- ePlex Revenues for Q4 were 412.1M an increase of 110% over prior year.
- Loss per share was reduced from 26c per share to 21c per share.
============
JPMorgan Healthcare Conference Picks and Trades: AMRN,GNMK,TDOC.
Many sector Indexes are up over 10% YTD: Small caps: IJR,IWM,XBI; NASDAQ-100 QQQ
Trending Up: Many mid-cap biopharmas on our watch list are still way below 2018 highs but many are recovering above the mid-point : ARRY, ARNA, GWPH, ICPT, INCY ,IONS, SRPT, SGEN, NVCR.
We attended the J.P.Morgan Healthcare Conference on January 7-9 and here we summarize some of our picks and trades.We attended over 25 presentations so we are only summarizing a select group. First here is the performance for the major ETFs over the past 5 days and YTD:
IBB up 3.4%, 13.75% YTD at $110.22.
XBI up 4.5% , 16.5% YTD at $84.78.
XLV up 2.2%, 4.8% YTD at $91.47.
Here are some the picks posted during the meeting. We are still long all of these stocks.
Amarin (AMRN) $17.35, bought at about $14.75. 52 week range $2.35-$23.34.
Amarin is focused on the development and commercialization of therapeutics for cardiovascular disease. The Company’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule for edice triglyceride levels. 2017 Revenues were running at $205.8M.
Teledoc Health, Inc. (TDOC) $66.58 bought at about $54.50. 52 week range $35.75-$89.05.
Teledoc Health, Inc.provides global telemedicine services covering 450 sub-specialties such as upper respiratory infections, cancer and congestive heart failure. The telehealth service are provided through mobile devices, Internet video and phone. Revenues were running at $372.3M growing at 61.6% QtQ.
GenMark Dagnostics, Inc, (GNMK) $6.07 bought at $6.22. 52 week range $3.58-$8.81.
GenMark Diagnostics is a molecular diagnostics Company based on a proprietary platform of e sensor electrochemical detection.The XT-8 instrument provides a broad panel of tests including NCV genotyping, cystic fibrosis, respiratory virus panel and warfarin sensitivity. Revenues were running at $67.4M with a QtQ growth of 36.2%
In addition we made the following new trades since the Conference at various prices and all are still longs: BAX,ILMN MRNA.
NOTE: The AGBT Meeting is on Tuesday FEB 19 so look for a strong tape for life science tools and molecular diagnostics stocks.
Advances in Genome Biology and Technology (AGBT) is considered the preeminent genome science and technology conference where top global researchers, leaders and innovators meet to announce new discoveries, cutting edge breakthroughs and to collaborate